Introduction: Viabahn VBX is a novel endograft with no longitudinal struts and heparin-bonded graft material.

Aim: To present our experience of Viabahn BX in 12 patients who underwent FB-EVAR.

Materials and Methods: Health Canada Investigational Testing Authorization from Feb 2017 to current. The efficacy, safety and clinical outcomes were assessed. Imaging follow-up of CTA and plain Xray at 1 week, 6 weeks and 6 mths.

Results: 12 pts (9 male), median age 78, mean aneurysm diameter 6.7cm. 6 juxtarenal, 6 TAA aneurysm (1 type 1, 2 type 3, 3 type 4). 8 fenestrated and 4 branched devices were used.

Stent Delivery/Deployment (44 units)
100% VBX stents were delivered to target vessel with no stent dislocation from the balloon. 100% of VBX deployed in target vessel.

Endoleaks
1 type 1b
2 type II (one needed embolization)
1 type III (failure to cannulate celiac)

Complications
One paraplegia
One duodenal ulcer (likely from common hepatic artery dissection)
One focal stomach and splenic infarct (likely from loss of splenic artery)
One renal VBX Stent thrombosis

Summary
Viabahn VBX has good trackability and delivery profile for FB-EVAR. Further study is required to determine long-term efficacy of the antithrombotic property of the graft material.